Free Trial

Chemomab Therapeutics (CMMB) Insider Trading & Ownership

Chemomab Therapeutics logo
$3.16 -0.26 (-7.48%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Chemomab Therapeutics (NASDAQ:CMMB) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
11.91%
Number Of
Insiders Buying
(Last 3 Years)
0
Number Of
Insiders Selling
(Last 3 Years)
3
Amount Of
Insider Selling
(Last 3 Years)
$1.89M
Get CMMB Insider Trade Alerts

Want to know when executives and insiders are buying or selling Chemomab Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CMMB Insider Buying and Selling by Quarter

Chemomab Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2023Israel Gp Ltd. OrbimedMajor ShareholderSell84,225$14.32$1,206,102.00  
11/16/2022George Adi MorInsiderSell81,193$8.32$675,525.76  
11/16/2022Neil Harris CohenDirectorSell602$8.00$4,816.00  
(Data available from 1/1/2013 forward)

CMMB Insider Trading Activity - Frequently Asked Questions

The list of insiders at Chemomab Therapeutics includes George Adi Mor, Israel Gp Ltd. Orbimed, and Neil Harris Cohen. Learn more on insiders at CMMB.

11.91% of Chemomab Therapeutics stock is owned by insiders. Learn more on CMMB's insider holdings.

Chemomab Therapeutics Key Executives

  • Dr. Adi Mor George Ph.D. (Age 42)
    Co-Founder, Chief Scientific Officer, CEO & Executive Director
    Compensation: $330k
  • Ms. Sigal Fattal CPA (Age 53)
    M.B.A., Chief Financial Officer
    Compensation: $322k
  • Dr. Matthew B. Frankel M.B.A. (Age 55)
    M.D., Chief Medical Officer & VP of Drug Development
    Compensation: $850k
  • Barbara Lindheim
    Consulting Vice President of Investor & Public Relations, Strategic Communications


This page (NASDAQ:CMMB) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners